Drugs / Acular LS
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | ACULAR LS | — | 2003-05-30 | fda.gov ↗ |
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy3 trials | ||||||
| Phase 2 | NCT01673191 Comparator | Nov 2012 → Dec 2014 | diabetes mellitus, macular retinal edema | Retinal Consultants of Arizona | Completed | No outcome recorded |
| Phase 4 | NCT00869219 Comparator | Mar → Aug 2009 | — | Santa Casa de Misericordia de Santos | Unknown | No outcome recorded |
| — | NCT00478036 Comparator | May 2007 → Jan 2014 | open-angle glaucoma | University of Colorado, Denver | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Acular LS | “NSAID eye drop: Acular LS” NCT01673191 ↗ |
| Route | Topical | “Acular LS - 1 drop in treated eye, 4 times a day, for 4 days” NCT00478036 ↗ |